BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 25918026)

  • 1. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
    Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
    Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
    Owada S; Tomita H; Kinjo T; Ishida Y; Itoh T; Sasaki K; Horiuchi D; Kimura M; Sasaki S; Okumura K
    Thromb Res; 2015 Jan; 135(1):62-7. PubMed ID: 25466835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Hapgood G; Butler J; Malan E; Chunilal S; Tran H
    Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
    Samoš M; Stančiaková L; Ivanková J; Staško J; Kovář F; Dobrotová M; Galajda P; Kubisz P; Mokáň M
    J Thromb Thrombolysis; 2015 Jan; 39(1):95-100. PubMed ID: 25103614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
    Kawabata M; Yokoyama Y; Sasano T; Hachiya H; Tanaka Y; Yagishita A; Sugiyama K; Nakamura T; Suzuki M; Isobe M; Hirao K
    J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
    Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
    Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
    Kate M; Szkotak A; Witt A; Shuaib A; Butcher K
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1351-5. PubMed ID: 24406026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
    van Ryn J; Grottke O; Spronk H
    Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
    Khadzhynov D; Wagner F; Formella S; Wiegert E; Moschetti V; Slowinski T; Neumayer HH; Liesenfeld KH; Lehr T; Härtter S; Friedman J; Peters H; Clemens A
    Thromb Haemost; 2013 Apr; 109(4):596-605. PubMed ID: 23389759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
    J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of Oral Thrombin Inhibitor].
    Matsuno K; Usami T; Hatuse M; Shimizu C
    Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
    Spannagl M; Bauersachs R; Debus ES; Gawaz M; Gerlach H; Haas S; Hach-Wunderle V; Lindhoff-Last E; Riess H; Schellong S; Schinzel H; Bode C
    Hamostaseologie; 2012; 32(4):294-305. PubMed ID: 23114798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
    Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
    Beliavskaia OO; Vavilova TV
    Angiol Sosud Khir; 2014; 20(4):37-41. PubMed ID: 25490355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
    Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
    Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran overdose secondary to acute kidney injury and amiodarone use.
    Fountzilas C; George J; Levine R
    N Z Med J; 2013 Mar; 126(1370):110-2. PubMed ID: 23474519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.